Cardiorenal interaction: Appropriate treatment of cardiovascular risk factors to improve outcomes in chronic kidney disease

Postgraduate Medicine

Volumn 122, Issue 2, 2010, Pages 25-34

  McCullough, Peter A ^a   Verrill, Thomas A ^a  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

Author keywords

Cardiovascular disease; Chronic kidney disease; Renin angiotensin aldosterone system blockade; Risk factors

Indexed keywords

ACETYLSALICYLIC ACID; ALBUMIN; ALDOSTERONE; ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENOXAPARIN; FIBRIC ACID DERIVATIVE; FIBRINOGEN RECEPTOR ANTAGONIST; GLICLAZIDE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INDAPAMIDE PLUS PERINDOPRIL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; PLACEBO; RENIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT;

ACUTE CORONARY SYNDROME; ALBUMINURIA; ANGINA PECTORIS; ARTICLE; BARE METAL STENT; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CIGARETTE SMOKING; CORONARY ARTERY RECANALIZATION; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DIABETIC NEPHROPATHY; DIASTOLIC BLOOD PRESSURE; DRUG ELUTING STENT; DYSLIPIDEMIA; GLOMERULUS FILTRATION RATE; GLYCEMIC CONTROL; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FUNCTION; HEART PROTECTION; HEMODIALYSIS; HOSPITAL CARE; HUMAN; HYPERNATREMIA; HYPERTENSION; IN-STENT RESTENOSIS; KIDNEY DISEASE; KIDNEY FAILURE; LIFESTYLE MODIFICATION; MORTALITY; PATIENT COUNSELING; PERCUTANEOUS CORONARY INTERVENTION; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RHABDOMYOLYSIS; RISK FACTOR; RISK MANAGEMENT; SMOKING CESSATION; STROKE; SYSTOLIC BLOOD PRESSURE; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; DRUG EFFECT; KAPLAN MEIER METHOD; LIFESTYLE; MULTIVARIATE ANALYSIS; REVIEW; RISK ASSESSMENT;

ACUTE CORONARY SYNDROME; ALBUMINURIA; ANTIHYPERTENSIVE AGENTS; ANTILIPEMIC AGENTS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIABETES MELLITUS; DYSLIPIDEMIAS; HUMANS; KAPLAN-MEIERS ESTIMATE; KIDNEY FAILURE, CHRONIC; LIFE STYLE; MULTIVARIATE ANALYSIS; PLATELET AGGREGATION INHIBITORS; PROGNOSIS; RENIN-ANGIOTENSIN SYSTEM; RISK ASSESSMENT; RISK FACTORS; SMOKING CESSATION;

EID: 77950342584     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2010.03.2119     Document Type: Article

References (112)

1. Herzog CA, Mangrum JM, Passman R. Sudden cardiac death and dialysis patients. Semin Dialysis. 2008;21(4):300-307.
2. McCullough PA, Sandberg KR. Chronic kidney disease and sudden death: strategies for prevention. Blood Purif. 2004;22(1):136-142.
3. Ronco C, Haapio M, House AA, Anavekar N, Bellomo R. Cardiorenal syndrome. J Am Coll Cardiol. 2008;52(19):1527-1539.
4. Van Dokkum RP, Eijkelkamp WB, Kluppel AC, et al. Myocardial infarction enhances progressive renal damage in an experimental model for cardio-renal interaction. J Am Soc Nephrol. 2004;15(12):3103-3110.
5. Schrier RW. Role of diminished renal function in cardiovascular mortality: marker or pathogenic factor? J Am Coll Cardiol. 2006;47(1):1-8.
6. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2 suppl 1):S1-S266.
7. McCullough PA. Cardiovascular disease in chronic kidney disease from a cardiologist's perspective. Curr Opin Nephrol Hypertens. 2004;13(6):591-600.
8. Adler AI, Stevens RJ, Manley SE, et al. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int. 2003;63(1):225-232.
9. McCullough PA, Li S, Jurkovitz CT, Stevens LA, et al; Kidney Early Evaluation Program Investigators. CKD and cardiovascular disease in screened high-risk volunteer and general populations: the Kidney Early Evaluation program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999-2004. Am J Kidney Dis. 2008;51(4 suppl 2):S38-S45.
10. McCullough PA, Jurkovitz CT, Pergola PE, et al; for the KEEP Investigators. Independent components of chronic kidney disease as a cardiovascular risk state: results from the Kidney Early Evaluation Program (KEEP). Arch Intern Med. 2007;167(11):1122-1129.
11. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu C. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351(13):1296-1305.
12. Plantinga LC, Miller ER, Stevens LA, et al; Centers for Disease Control and Prevention Chronic Kidney Disease Surveillance Team. Blood pressure control among persons without and with chronic kidney disease: US trends and risk factors 1999-2006. Hypertension. 2009;54(1):47-56.
13. Sarnak MJ, Levey AS, Schoolwerth AC, et al; American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation. 2003;108(17):2154-2169.
14. Agarwal R, Nissenson AR, Batlle D, Coyne DW, Trout JR, Warnock DG. Prevalence, treatment, and control of hypertension in chronic hemodialysis patients in the United States. Am J Med. 2003;115(4):291-297.
15. McCullough PA, Sandberg KR, Yee J, Hudson MP. Mortality benefit of angiotensin-converting enzyme inhibitors after cardiac events in patients with end-stage renal disease. J Renin Angiotensin Aldosterone Syst. 2002;3(3):188-191.
16. Vlahakos DV, Hahalis G, Vassilakos P, Marathias KP, Geroulanos S. Relationship between left ventricular hypertrophy and plasma renin activity in chronic hemodialysis patients. J Am Soc Nephrol. 1997;8(11):1764-1770.
17. Toto R. Angiotensin II subtype 1 receptor blockers and renal function. Arch Intern Med. 2001;161(12):1492-1499.
18. Brenner BM, Cooper ME, de Zeeuw D; RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345(12):861-869.
19. Lewis EJ, Hunsicker LG, Clarke WR; Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345(12):851-860.
20. Parving HH, Lehnert H, Bröchner-Mortensen J; Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345(12):870-878.
21. Dahlof B, Devereux RB, Kjeldsen SE; LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359(9311):995-1003.
22. Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med. 2001;134(8):629-636.
23. Hampl H, Sternberg C, Berweck S, et al. Regression of left ventricular hypertrophy in hemodialysis patients is possible. Clin Nephrol. 2002;58(suppl 1):S73-S96.
24. Agodoa LY, Appel L, Bakris GL, et al; African American Study of Kidney Disease and Hypertension (AASK) Study Group. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA. 2001;285(21):2719-2728.
25. Mann JF, Schmieder RE, McQueen M, et al; ONTARGET investigators. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet. 2008;372(9638):547-553.
26. Fichett D. Results of the ONTARGET and TRANSCEND studies: an update and discussion. Vasc Health Risk Manag. 2009;5(1):21-29.
27. Navaneethan SD, Nigwekar SU, Sehgal AR, Strippoli GF. Aldosterone antagonists for preventing the progression of chronic kidney disease. Cohrane Database Syst Rev. 2009;3:CD007004.
28. McCullough PA. Chronic kidney disease: tipping the scale to the benefit of angiotensin-converting enzyme inhibitors in patients with coronary artery disease. Circulation. 2006;114(1):6-7.
29. Young JB, Dunlap ME, Pfeffer MA, et al; Candesartan in Heart Failure Assessment of Reduction in Mortality and morbidity (CHARM) Investigators and Committees. Circulation. 2004;110(17):2618-2626.
30. Li PK, Chow KM, Wong TY, et al. Effects of an angiotensin-converting enzyme inhibitor on residual renal function in patients receiving peritoneal dialysis. A randomized, controlled study. Ann Intern Med. 2003;139(2):105-112.
31. Bakris GL. Role for beta-blockers in the management of diabetic kidney disease. Am J Hypertens. 2003;16(9 pt 2):7S-12S.
32. Cice G, Ferrara L, D'Andrea A, et al. Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial. J Am Coll Cardiol. 2003;41(9):1438-1444.
33. Weber MA. New opportunities in cardiovascular patient management: a survey of clinical data on the combination of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Am J Cardiol. 2007;100(3A):45J-52J.
34. Unger T, Stoppelharr M. Rationale for double renin-angiotensinaldosterone system blockade. Am J Cardiol. 2007;100:25J-31J.
35. Cohn JN, Goldman JM. Establishing a new option for target-organ protection: rationale for ARB plus ACE inhibitor combination therapy. Am J Hypertens. 2008;21(3):248-256.
36. Whaley-Connell A, Pavey BS, Chaudhary K, Saab G, Sowers JR. Renin-angiotensin-aldosterone system intervention in the cardiometabolic syndrome and cardio-renal protection. Ther Adv Cardiovasc Dis. 2007;1(1):27-35.
37. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK; AVOID Study Investigators. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med. 2008;358(23):2433-2446.
38. Oparil S, Yarows SA, Patel S, Fang H, Zhang J, Satlin A. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomized, double-blind trial. Lancet. 2007;370(9583):221-229.
39. Pool JL, Schmieder RE, Asisi M, et al. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. Am J Hypertens. 2007;20(1):11-20.
40. McCullough PA, Sandberg KR, Borzak S, et al. Benefits of aspirin and beta-blockade after myocardial infarction in patients with chronic kidney disease. Am Heart J. 2002;144(2):226-232.
41. National Institutes of Health. US Renal Data System. USRDS 2009 Annual Data Report: Atlas of chronic kidney disease and end-stage renal disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2009.
42. Harper CR, Jacobson TA. Managing dyslipidemia in chronic kidney disease. J Am Coll Cardiol. 2008;51(25):2375-2384.
43. National Kidney Foundation. K/DOQI clinical practice guidelines for managing dyslipidemias in chronic kidney disease. Am J Kidney Dis. 2003;41(suppl 4):S1-S92.
44. Chen J, Muntner P, Hamm LL, et al. The metabolic syndrome and chronic kidney disease in US adults. Ann Intern Med. 2004;140(3):167-174.
45. Buemi M, Senatore M, Corica F, et al. Statins and progressive renal disease. Med Res Rev. 2002;22(1):76-84.
46. Oda H, Keane WF. Recent advances in statins and the kidney. Kidney Int Suppl. 1999;71:S2-S5.
47. Keech A, Simes RJ, Barter P, et al; FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomized controlled trial. Lancet. 2005;366(9500):1849-1861.
48. Saha SA, Arora RR. Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus-a pooled meta-analysis of randomized placebo-controlled clinical trials [published online ahead of print February 16, 2009]. Int J Cardiol.
49. Allemann S, Diem P, Egger M, Christ ER, Stettler C. Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus: meta-analysis of randomized controlled trials. Curr Med Res Opin. 2009;22(3):617-623.
50. Wu J, Song Y, Li H, Chen J. Rhabdomyolysis associated with fibrate therapy: review of 76 published cases and a new case report. Eur J Clin Pharmacol. 2009;65(12):1169-1174.
51. Tonelli M, Isles C, Curhan GC, et al. Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation. 2004;110:1557-1563.
52. Tonelli M, Keech A, Shepherd J, et al. Effects of pravastatin in people with diabetes and chronic kidney disease. J Am Soc Nephrol. 2005;16(12):3748-3754.
53. Tonelli M, Isles C, Craven T, et al. Effect on pravastatin on rate of kidney function loss in people with or at risk for coronary disease. Circulation. 2005;112(2):171-178.
54. Navaneethan SD, Pansini F, Perkovic V, et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev. 2009;2:CD007784.
55. Nakamura H, Mizuno K, Ohashi Y, Yoshida T, Hirao K, Uchida Y; MEGA Study Group. Pravastatin and cardiovascular risk in moderate chronic kidney disease. Atherosclerosis. 2009;206(2):512-517.
56. Sandhu S, Wiebe N, Fried LF, Tonelli M. Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol. 2006;17:2006-2016.
57. Fried LF, Orchard TJ, Kasiske BL. Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int. 2001;59(1):260-269.
58. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA. 2003;289(13):1681-1690.
59. Shek A, Ferrill MJ. Statin-fibrate combination therapy. Ann Pharmacother. 2001;35(7-8):908-917.
60. Fellstrom BC, Jardine AG, Schmieder RE; AURORA Study Group. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360(14):1395-1407.
61. Wanner C, Krane V, März W, et al; German Diabetes and Dialysis Study Investigators. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353(3):238-248.
62. McCullough PA, Agarwal M, Agrawal V. Review article: risks of coronary artery calcification in chronic kidney disease: do the same rules apply? Nephrology (Carlton). 2009;14(4):428-436.
63. Hanratty R, Chonchol LM, Dickinson M, et al. Incidence chronic kidney disease and the rate of kidney function decline in individuals with hypertension [published online ahead of print November 4, 2009]. Nephrol Dial Translpant.
64. Whaley-Connell AT, Sowers JR, McFarlane SI, et al; Kidney Early Evaluation Program Investigators. Diabetes mellitus in CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999-2004. Am J Kidney Dis. 2008;51(S2):S21-S29.
65. Gerstein HC, Mann JFE, Yi Q, et al; HOPE study investigators. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA. 2001;286(4):421-426.
66. Gæde P, Vedel P, Larsen N, Jensen GV, Parving HH, Penderson O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348(5):383-393.
67. Gaede P, Lund-Anderson H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358(6):580-591.
68. Meier M, Hummel M. Cardiovascular disease and intensive glucose control in type 2 diabetes mellitus: moving practice toward evidencebased strategies. Vasc Health Risk Manag. 2009;5:859-871.
69. Skyler JS, Bergenstal R, Bonow RO, et al; American Diabetes Association; American College of Cardiology Foundation; American Heart Association. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care. 2009;32(4):187-192.
70. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837-853.
71. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577-1588.
72. Brosius FC 3rd, Hostetter TH, Kelepouris E, et al. Detection of chronic kidney disease in patients with or at increased risk of cardiovascular disease: a science advisory from the American Heart Association Kidney And Cardiovascular Disease Council; the Councils on High Blood Pressure Research, Cardiovascular Disease in the Young, and Epidemiology and Prevention; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: developed in collaboration with the National Kidney Foundation. Circulation. 2006;114(10):1083-1087.
73. Arnlöv J, Evans JC, Meigs JB, et al. Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals. Circulation. 2005;112(7):969-975.
74. Gerstein HC, Mann JF, Yi Q, et al; HOPE Study Investigators. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA. 2001;286(4):421-426.
75. de Zeeuw D, Remuzzi G, Parving HH, et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation. 2004;110(8):921-927.
76. de Jong PE, Curhan GC. Screening, monitoring, and treatment of albuminuria: public health perspectives. J Am Soc Nephrol. 2006;17(8):2120-2126.
77. Asselbergs FW, Diercks GF, Hillege HL, et al; Prevention of Renal and Vascular Endstage Disease Intervention Trial (PREVEND IT) Investigators. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation. 2004;110(18):2809-2816.
78. Biesenbach G, Zazgornik J. Influence of smoking on the survival rate of diabetic patients requiring hemodialysis. Diabetes Care. 1996;19(6):625-628.
79. Orth SR, Ritz E. The renal risks of smoking: an update. Curr Opin Nephrol Hypertens. 2002;11(5):483-488.
80. Rigotti NA. Helping smokers with cardiac disease abstain from tobacco after a stay in hospital. CMAJ. 2009;180(13):1283-1284.
81. Spinler SA, Mahaffey KW, Gallup D, et al; SYNGERY Trial Investigators. Relationship between renal function and outcomes in high-risk patients with non-ST-segment elevation acute coronary syndromes: Results from SYNERGY [published online ahead of print April 28, 2009]. Int J Cardiol.
82. Vasu S, Gruberg L, Brown DL. The impact of advanced chronic kidney disease on in-hospital mortality following percutaneous coronary intervention for acute myocardial infarction. Catheter Cardiovasc Interv. 2007;70(5):701-705.
83. Best PJ, Berger PB, Davis BR, et al; PRESTO Investigators. Impact of mild or moderate chronic kidney disease on the frequency of restenosis: results from the PRESTO trial. J Am Coll Cardiol. 2004;44(9):1786-1791.
84. Bonello L, DeLabriolle A, Roy P, et al. Impact of optimal medical therapy and revascularization on outcome of patients with chronic kidney disease and on dialysis who presented with acute coronary syndrome. Am J Cardiol. 2008;102(5):535-540.
85. Mohiuddin SM, Mooss AN, Hunter CB, Grollmes TL, Cloutier DA, Hilleman DE. Intensive smoking cessation intervention reduces mortality in high risk smokers with cardiovascular disease. Chest. 2007;131(2):464-452.
86. Rigotti NA, Munafo MR, Stead LF. Interventions for smoking cessation in hospitalized patients. Cochrane Database Syst Rev. 2007;3:CD001837.
87. Weisman SM, Graham DY. Evaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular events. Arch Intern Med. 2002;162(19):2197-2202.
88. Berger JS, Brown DL, Becker RC. Low-dose aspirin in patients with stable cardiovascular disease: a meta-analysis. Am J Med. 2008;121(1):43-49.
89. Patrono C, Coller B, FitzGerald GA, Hirsh J, Roth G. Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3 suppl):234S-264S.
90. Winchester JF. Therapeutic uses of aspirin in renal diseases. Am J Kidney Dis. 1996;28(1 suppl 1):S20-S23.
91. Kaufman JS, Fiore L, Hasbargen JA, O'Connor TZ, Perdriset G. A pharmacodynamic study of clopidogrel in chronic hemodialysis patients. J Thromb Thrombolysis. 2000;10(2):127-231.
92. Best PJ, Steinhubl SR, Berger PB, et al; CREDO investigators. The efficacy and safety of short-and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. Am Heart J. 2008;155(4):687-693.
93. Tadros GM, Herzog CA. Percutaneous coronary intervention in chronic kidney disease patients. J Nephrol. 2004;17(3):364-368.
94. Gibson CM, Pinto DS, Murphy SA, et al. Association of creatinine and creatinine clearance on presentation in acute myocardial infarction with subsequent mortality. J Am Coll Cardiol. 2003;42:1535-1543.
95. Januzzi JL, Cannon CP, DiBattiste PM, Murphy S, Weintraub W, Braunwald E; TACTICS-TIMI 18 Investigators. Effects of renal insufficiency on early invasive management in patients with acute coronary syndromes (The TACTICS-TIMI 18 Trial). Am J Cardiol. 2002;90(11):1246-1249.
96. Ix JH, Mercado N, Shlipak MG, et al. Association of chronic kidney disease with clinical outcomes after coronary revascularization: the arterial revascularization therapies study (ARTS). Am Heart J. 2005;149(3):512-519.
97. Herzog CA, Ma JZ, Collins AJ. Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. N Engl J Med. 1998;339(12):799-805.
98. Winkelmayer WC, Charytan DM, Brookhart MA, Levin R, Solomon DH, Avorn J. Kidney function and use of recommended medications after myocardial infarction in elderly patients. Clin J Am Soc Nephrol. 2006;1(4):796-801.
99. Chayrtan D, Mauri L, Agarwal A, Servoss S, Scirica B, Kuntz RE. The use of invasive cardiac procedures after acute myocardial infarction in long-term dialysis patients. Am Heart J. 2006;152(3):558-564.
100. Berter AK, Duval S, Krumholtz HM. Aspirin, beta-blockers, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction. J Am Coll Cardiol. 2003;42(2):201-208.
101. Schiele F, Legalery P, Didier K, et al. Impact of renal dysfunction on 1-year mortality after acute myocardial infarction. Am Heart J. 2006;151(3):661-667.
102. Keeley EC, Kadakia R, Soman S, Borzak S, McCullough PA. Analysis of long-term survival after revascularization in patients with chronic kidney disease presenting with acute coronary syndromes. Am J Cardiol. 2003;92(5):509-514.
103. Anavekar N, McMurray JJ, Velazquez EJ, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med. 2004;351(13):1285-1295.
104. Shlipak MG. Pharmacotherapy for heart failure in patients with renal insufficiency. Ann Intern Med. 2003;138(11):917-924.
105. McCullough PA. Acute coronary syndromes in patients with renal failure. Curr Cardiol Rep. 2003;5(4):266-270.
106. Stigant C, Izadnegahdar M, Levin A, Buller CE, Humphries KH. Outcomes after percutaneous coronary interventions in patients with CKD: improved outcome in the stenting era. Am J Kidney Dis. 2005;45(6):1002-1009.
107. Bevc S, Penko M, Kanic V, Hojs R. Mortality of patient with renal dysfunction after percutaneous coronary intervention. Angiology. 2010;61(1):24-30.
108. Keeley EC, Kadakia R, Soman A, Borzak S, McCullough PA. Analysis of long-term survival after revascularization in patients with chronic kidney disease presenting with acute coronary syndromes. Am J Cardiol. 2003;92(5):509-514.
109. Lemos PA, Arampatzis CA, Hoye A, et al. Impact of baseline renal function on mortality after percutaneous coronary intervention with sirolimus-eluding stents or bare metal stents. Am J Cardiol. 2005;95(2):167-172.
110. Nakazawa G, Tanabe K, Aoki J, et al. Impact of renal insufficiency on clinical and angiographic outcomes following percutaneous coronary intervention with sirolimus-eluting stents. Catheter Cardiovasc Interv. 2007;69(6):808-814.
111. Ota T, Umeda H, Yokota S, et al. Relationship between severity of renal impairment and 2-year outcomes after sirolimus-eluting stent implantation. Am Heart J. 2009;158(1):92-98.
112. Jeong YH, Hong MK, Lee CW, et al. Impact of significant chronic kidney disease on long-term clinical outcomes after drug-eluting stent versus bare metal stent implantation. Int J Cardiol. 2008;125(1):36-40.